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Abstract
Background: MicroRNAs (miRNAs) regulate gene expression and influence cancer. Primary transcripts of miRNAs
(pri-miRNAs) are poorly annotated and little is known about the role of germline variation in miRNA genes and
breast cancer (BC). We sought to identify germline miRNA variants associated with BC risk and tumor subtype
among African-American (AA) women.
Methods: Under the African American Breast Cancer Epidemiology and Risk (AMBER) Consortium, genotyping and
imputed data from four studies on BC in AA women were combined into a final dataset containing 224,188 miRNA gene
single nucleotide polymorphisms (SNPs) for 8350 women: 3663 cases and 4687 controls. The primary miRNA sequence
was identified for 566 miRNA genes expressed in Encyclopedia of DNA Elements (ENCODE) Tier 1 cell types and human
pancreatic islets. Association analysis was conducted using logistic regression for BC status overall and by tumor subtype.
Results: A novel BC signal was localized to an 8.6-kb region of 17q25.3 by four SNPs (rs9913477, rs1428882938, rs28585511,
and rs7502931) and remained statistically significant after multiple test correction (odds ratio (OR) = 1.44, 95% confidence
interval (CI) = 1.26–1.65; p = 3.15 × 10−7; false discovery rate (FDR) = 0.03). These SNPs reside in a genomic location that
includes both the predicted primary transcript of the noncoding miRNA gene MIR3065 and the first intron of the gene for
brain-specific angiogenesis inhibitor 1-associated protein 2 (BAIAP2). Furthermore, miRNA-associated SNPs on chromosomes
1p32.3, 5q32, and 3p25.1 were the strongest signals for hormone receptor, luminal versus basal-like, and HER2 enrichment
status, respectively. A second phase of genotyping (1397 BC cases, 2418 controls) that included two SNPs in the 8.6-kb
region was used for validation and meta-analysis. While neither rs4969239 nor rs9913477 was validated, when meta-
analyzed with the original dataset their association with BC remained directionally consistent (OR = 1.29, 95% CI = 1.16–1.44
(p= 4.18 × 10–6) and OR= 1.33, 95% CI = 1.17–1.51 (p= 1.6 × 10–5), respectively).
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Conclusion: Germline genetic variation indicates that MIR3065 may play an important role in BC development and
heterogeneity among AA women. Further investigation to determine the potential functional effects of these SNPs is
warranted. This study contributes to our understanding of BC risk in AA women and highlights the complexity in evaluating
variation in gene-dense regions of the human genome.
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Background
MicroRNAs (miRNAs) are small noncoding RNAs that were
formally recognized in 2001 [1] as one of the largest classes
of gene regulators in eukaryotes [2]. miRNAs undergo a
complex, multistep process of biogenesis summarized by Lin
and Gregory in 2015 [3]. Briefly, within the nucleus, a
primary miRNA transcript (pri-miRNA)—usually several
hundred nucleotides (nt) to greater than 1 megabase (Mb) in
length—is cleaved to create a precursor miRNA (pre-
miRNA) approximately 70 nt in length which folds to form a
stem-loop intermediate. This intermediate is exported from
the nucleus and further processed to a miRNA duplex, ap-
proximately 22 nt in length. One strand of the miRNA du-
plex is loaded onto the RNA-induced silencing complex
(RISC) to form a functional mature miRNA. Cleavage and
processing of the pri- and pre-miRNA require sequence and
secondary structure recognition by several RNA-binding
proteins and their partners. Approximately 30% of mature
miRNAs are processed from introns or exons of coding
genes, while the remaining miRNAs are intergenic and
expressed from independent transcription units. Mature
miRNAs bind to the 3’ untranslated region (UTR) of target
genes to silence them by either translational repression or
messenger RNA (mRNA) degradation [4]. There are over
2500 identified human miRNAs [5] and each may bind to
hundreds or even thousands of different target genes, coord-
inating expression of a large number of mRNAs; this makes
them key players in gene regulatory networks [3].
miRNAs have been shown to influence numerous mo-
lecular pathways and pathological conditions, including
cancer [3, 6–10], and can function as both oncogenes and
tumor suppressors depending on the context. Furthermore,
oncoproteins such as MYC bind to the promoters of key
miRNAs, activating oncogenic miRNAs (oncomiRs) and
downregulating tumor suppressor miRNAs [11–13]. In
breast cancer (OMIM #114480), miRNAs have been impli-
cated in the regulation of genes involved in pathways critic-
ally relevant to disease etiology and severity including
apoptosis, cell cycle checkpoints, cell migration, invasion,
and metastasis [14–17]. To a large extent, the miRNA
repertoire that is present in normal and paired tumor tissue
from the same organ is quite similar; however, specific
miRNAs are often aberrantly elevated or suppressed in the
tumor [18]. In 2011, Persson et al. performed one of the
first comprehensive characterizations via next-generation
sequencing (NGS) of miRNAs in paired normal and tumor
breast tissue and identified 361 new miRNAs [18]. While
the functionality of some of the miRNAs identified by deep
sequencing remains unknown, about two-thirds of these
newly identified miRNAs were expressed in other tissues,
and nearly half were associated with components of the
RISC and were found in estrogen receptor-positive, invasive
breast ductal carcinoma cells. Germline single nucleotide
polymorphisms (SNPs) in critical regions of miRNA genes
including the promoter and primary transcripts may
contribute to the dysregulation in miRNA biogenesis and
expression differences common in breast cancer.
Over the last decade there has been tremendous
progress made in the field of miRNAs and cancer, par-
ticularly centered on miRNA expression patterns that
are emerging as promising diagnostic tools and predict-
ive markers because of their correlation with cancer pro-
gression and patient survival [3]. However, little is
known about the role of germline variation in miRNAs
and susceptibility to cancer.
Currently, known germline genetic variation primarily
from studies of European women explains only 50% of the
familial aggregation of breast cancer (BC), suggesting that
numerous other susceptibility gene variants have yet to be
uncovered [19]. Several molecular epidemiologic studies
have assessed the association of common germline
miRNA gene variation in mature and precursor miRNA
sequences with disease risk, including BC [20–29]. Few
epidemiologic studies have evaluated the association
between a large number of germline genetic variants in
the promoter and primary sequences of miRNAs and BC
risk, particularly among African-American (AA) women.
We sought to identify large numbers of germline miRNA
gene variants associated with BC risk and subtype among
women participating in a large AA BC consortium.
Methods
Study population
This research was conducted using data from the African
American Breast Cancer Epidemiology and Risk (AMBER)
Consortium, a collaboration of two case-control studies of
BC in AA women (the Carolina Breast Cancer Study
(CBCS) [30] and the Women’s Circle of Health Study
(WCHS) [31, 32]) and two cohort studies (the Black
Women’s Health Study (BWHS) [33] and the Multiethnic
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Cohort (MEC) [34]). AMBER has been described previ-
ously [35]. All study participants provided written in-
formed consent and all studies obtained Institutional
Review Board approval.
This analysis utilizes data from 3663 cases and 4687
controls in AMBER who provided either blood or saliva
for DNA analysis. For the case-control studies, controls
were identified either through Division of Motor
Vehicles lists (age < 65 years) and Health Care Financing
Administration lists (age ≥ 65) (CBCS), or random digit
dialing and community controls (WCHS). For BWHS
and MEC, controls were chosen from among women
without BC, and were frequency matched to cases on
geographical region, sex, race, and 5-year age group.
Eligible cases were AA women with incident invasive BC
or ductal carcinoma in situ (DCIS). Estrogen receptor
(ER), progesterone receptor (PR), epidermal growth fac-
tor receptor 2 (HER2) receptor, and invasive status for
cases was determined using pathology data from hospital
or cancer registry records.
Genotyping and quality control (QC)
Genotyping of DNA from participants in the BWHS,
CBCS, and WCHS was performed by the Center for
Inherited Disease Research (CIDR) using the Illumina Hu-
man Exome BeadChip v1.1. This array includes > 200,000
coding variants, as well as tag SNPs for genome-wide
association study (GWAS) hits, a grid of common
variants, and ancestry informative markers (AIMs). A
description of the exome chip design is available from
http://genome.sph.umich.edu/wiki/Exome_Chip_Design.
In addition to the standard BeadChip, the chip included
approximately 159,000 SNPs of custom content focused
on BC pathways (e.g., steroid hormone metabolism, insu-
lin and insulin-like growth factors, inflammatory and im-
mune factors, and vitamin D).
A total of 405,555 SNPs were genotyped, and 300,008
SNPs remained after excluding variants that failed technical
filters imposed by CIDR, or QC filters recommended by
the University of Washington. Briefly, genotypes with a
GenCall score < 0.15 were classified as missing, and SNPs
were removed if they were monomorphic, had poor cluster
properties (ex. cluster separation < 0.2 or < 0.3 depending
on allele frequency), call rates < 0.98, Hardy-Weinberg
Equilibrium p < 1 × 10−4, > 1 Mendelian error in trios from
HapMap, or > 2 discordant calls in duplicate samples.
Mitochondrial and Y chromosome SNPs were also
removed. Genotypes were attempted for 6936 participants
from the BWHS, CBCS, and WCHS, and were completed
with a call rate > 98% for 6828 participants, which included
3130 cases (963 ER negative, 1674 ER positive, 493 ER
unknown) and 3698 controls. Imputation was performed
by the University of Washington using the IMPUTE2
software [36] and the 1000 Genomes Phase I reference
panel (5/21/2011 1000 Genomes data, December 2013
haplotype release).
Genetic data from 533 cases (135 ER negative, 309
ER positive, and 89 ER unknown) and 989 controls in
the MEC were available from a previous GWAS on
the Illumina Human 1 M-Duochip [37]. SNPs from
MEC were imputed to the same release of 1000 Ge-
nomes and combined with the genotype data from
the Illumina Human Exome BeadChip v1.1. Add-
itional exclusion criteria applied to the four-study
merged dataset were: variants with mismatching al-
leles or allele frequencies that were different by more
than 0.15 in MEC when compared with the other
three studies; variants with allele frequencies < 0.5%;
and variants with imputation score INFO < 0.5 in ei-
ther MEC or any of the other three studies. The final
merged dataset included genotypes from 8350 women,
3663 cases (1983 ER positive, 1098 ER negative, 582
unknown), and 4687 controls.
miRNA annotation, SNP selection and QC
Among the genotyped and imputed SNPs, miRNA
variants were defined as those within promoter, pri-
miRNA, pre-miRNA, mature, or downstream regions
of a known human miRNA. Mature and pre-miRNA
sequence locations were identified from the miRNA
database, miRBase release 21 [5, 38] . Pri-miRNAs
were identified by integrative analysis of chromatin
immunoprecipitation and massively parallel DNA se-
quencing (ChIP-seq) data from the Encyclopedia of
DNA Elements (ENCODE) project using an algorithm
described previously [39]. Five hundred and sixty six
miRNA genes with pri-miRNA sequence expressed in
six cell lines and tissue types (all ENCODE Tier 1 cell
types plus human pancreatic islets) were the focus of
this analysis. We extended the pri-miRNA 5 kilobases
(kb) upstream of the 5′-end (putative promoter) and
1 kb downstream of the 3′-end (additional putative
regulatory region). Variants that could be defined as
having multiple miRNA locations were defined by
their most unique location with the following priority:
mature > precursor > primary > promoter > down-
stream. For example, a variant in the mature miRNA
sequence is also by default in the pri-miRNA; how-
ever, according to our prioritization it would be de-
fined as a mature miRNA sequence variant. SNPs
were restricted to those variants with minor allele fre-
quencies (MAF) ≥ 1%. Annotation defined a total of
224,188 miRNA gene SNPs, with MAF ≥ 1%, from the
following miRNA gene regions: 10,435 promoter,
182,593 primary, 272 precursor, 158 mature, and 2150
downstream variants. The impact of genotype plat-
form was evaluated by quantile-quantile plots both
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with and without MEC genotypes, both yielding a
lambda = 0.991.
Association analysis
Single variant analyses were conducted using logistic regres-
sion as implemented in PLINK version 1.07. Models were
adjusted for age group (by ~ 10-year intervals), study site,
geographic group of residence, DNA source, and ancestry by
including principal components 5, 6, and 8 in the model
given their association with BC at p < 0.1 [40]. Models were
run for all cases versus all controls and for all hormone re-
ceptor subtyped (ER, PR, and HER2) cases versus controls,
respectively. Additional models were run for case-only sub-
type analyses (n= 3663, eligible cases with biomarker and co-
variate information) using ER, PR, and HER2 receptor
marker status. Specifically, the following three case-only sub-
type analyses were performed: 1) hormone receptor positive
(ER positive or PR positive, n= 2081) versus hormone recep-
tor negative (ER negative and PR negative, n= 997); 2) lu-
minal (ER positive or PR positive, n= 1613) versus basal-like
(ER negative, PR negative, and HER2 negative, n= 405) [41];
and 3) HER2 enriched (n = 1356) versus HER2 negative
(n = 344). P values were corrected within subtype ana-
lyses for multiple comparisons using the false discovery
rate (FDR) at 5% [42]. In all analyses, both invasive and
in situ cases were combined.
Validation and meta-analysis
A second phase of genotyping (1397 BC cases, 2418
controls) conducted in three of the four studies
within AMBER (CBCS, WCHS, and BWHS) on the
Illumina’s Infinium Multi-Ethnic Genotyping Array
(MEGA) Chip that included study-specific content
and SNPs rs4969239 and rs9913477 was used for val-
idation and meta-analysis. Similar to the association
analysis, logistic regression implemented in PLINK
version 1.07 was used and models were adjusted for
age group (by ~ 10-year intervals), study site, DNA
source, and ancestry by including principal compo-
nent 1 in the model given its association with BC at
p < 0.1. Validation for each variant was evaluated for
directional consistency and tested at the p < 0.05 level.
In the meta-analysis, both the original and the second
phase of genotyping were combined and the p value
corrected for multiple comparisons using an FDR at
5% [42].
Power was calculated for detecting an odds ratio (OR)
of 1.44 and an OR of 1.30 (a 10% reduction in effect esti-
mate assuming the original OR is an overestimate of the
actual effect) using a two-sided, p = 0.05 significance,
log-additive mode of inheritance, allele frequency of 0.06
(the same as rs9913477 MAF in the study population),
control to case ratio of 1.7 with 1397 cases, and preva-
lence of disease of 10%.
Results
Table 1 provides a distribution of key characteristics of
the study population by case or control status and in-
cludes age at diagnosis, study site, DNA source, as well
as clinical parameters (tumor stage and receptor status).
The study population originates from a broad geograph-
ical region of the United States with most cases from the
Northeast and South. Overall, the vast majority of the
cases have known ER or PR receptor status; however,
over half do not have known HER2 receptor status.
Among cases with known receptor status for all three
markers, approximately 20% are triple negative.
Genomic location of novel miRNA SNPs associated with
BC in African-American women: case-control analysis
The main case-control association analysis identified seven
SNPs (five imputed and two genotyped) in a 16.5-kb region
on chromosome 17q25.3 (Fig. 1 and Table 2), with imputed
rs9913477 (INFO r2 = 0.99; MAF= 0.06; OR = 1.44, 95%
confidence interval (CI) = 1.26–1.65; p = 3.15 × 10−7;
FDR = 0.03) emerging as the top hit. Following FDR
correction, four of the seven remained significantly
associated with BC risk, spanning an 8.6-kb region
(Table 2). All four SNPs reside in a genomic region
that includes the first intron of the brain-specific angiogen-
esis inhibitor 1-associated protein 2 (BAIAP2), as well as the
predicted primary transcript for MIR3065. Linkage disequi-
librium (LD) between the top hit (rs9913477) and the other
three statistically significant SNPs was high (r2 = 0.94) for
two (rs1428882938 and rs28585511) and perfect (r2 = 1.0)
for the third (rs7502931), suggesting they are all tagging the
same signal in this population. Subsequently, ER/PR subtype
analysis was conducted for all seven SNPs with p < 5 × 10–6
in the full analysis (Additional file 1: Table S1) and identified
that the signal and pattern of association in this region was
statistically significant based on FDR in ER+ versus controls,
most likely because it had the largest sample size. While the
other subtype analyses versus controls were not significant,
the magnitude of the odds ratio was similar to that observed
in ER+ versus controls. However, when we look at the case-
only subtype analyses (e.g., ER+ versus ER–, PR+ versus PR–)
we see a reduction in the magnitude of the odds
ratio suggesting that this region is more likely to be
associated generally with the development of breast
cancer rather than a particular subtype. Additionally, in a
subanalysis of ER positive cases (n = 1983) versus controls
(n = 4687) and PR positive cases (n = 1580) versus controls
(n = 4687) the same 17q25.3 locus top hit (rs9913477)
emerged, but was statistically significantly associated with
BC after FDR correction only for the largest subgroup of
ER positive cases (INFO r2 = 0.99, MAF = 0.58; OR = 1.53,
95% CI = 1.30–1.81; p = 4.29 × 10–7; FDR = 0.027). The
variant rs9913477 was also the second most significant
SNP in the ER positive plus PR-positive case group versus
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Table 1 Characteristics of the study population
Controls (n = 4687) Cases (n = 3663)
Frequency Mean (SD) or % Frequency Mean (SD) or %
Age at enrollment (years) 4687 55.62 (12.01) 3663 54.94 (11.74)
Age at enrollment (years)
18–29 24 0.51 30 0.82
30–39 396 8.45 306 8.35
40–49 1107 23.62 945 25.8
50–59 1461 31.17 1087 29.68
60–69 986 21.04 819 22.36
70–79 609 12.99 433 11.82
80+ 104 2.22 43 1.17
DNA source
Blood 1817 38.77 1961 53.54
Mouthwash 2243 47.86 853 23.29
Saliva 627 13.38 849 23.18
Study
BWHS 2249 48.98 901 24.6
WCHS 834 17.79 821 22.41
CBCS 615 13.12 1408 38.44
MEC 989 21.1 533 14.55
Location
New Jersey (NJ) 573 12.23 613 16.73
Northeast (except NJ) 1245 26.56 441 12.04
South 1476 31.49 1720 46.96
Midwest 238 5.08 200 5.46
West 1155 24.64 689 18.81
Stage
In situ NA 376 10.26
Invasive NA 2528 69.01
Unknown NA 759 20.72
Tumor receptor status
ER
Positive NA 1983 54.14
Negative NA 1098 29.98
Unknown NA 582 15.89
PR
Positive NA 1580 43.13
Negative NA 1343 36.66
Unknown NA 740 20.2
HER2
Positive NA 344 9.39
Negative NA 1356 37.02
Unknown NA 1963 53.59
Triple negative
Yes NA 405 11.06
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control analysis but did not reach statistical significance
after FDR correction (data not shown). In the ER negative,
PR-negative, and ER negative plus PR-negative cases ver-
sus control analysis, rs80339298 located in the primary se-
quence of MIR761 on chromosome 1 emerged as the top
SNP but did not reach statistical significance after FDR
correction (data not shown).
Case-only subtype analysis
Top SNPs identified in each of the three subtype analyses
are provided in Table 3. These top SNPs were located on
chromosomes 1p32.3 (rs80339298, OSBPL9 intron 11, NT_
032977.10), 5q32 (rs147821319, PPARGC1B intron 7, NM_
001172698), and 3p25.1 (rs116367195, intergenic between
BTD and ANKRD2, NM_001195099) from the GRCh38.p2
assembly for hormone receptor, luminal versus basal-like,
and HER2 enrichment status, respectively. All three SNPs
were low frequency (MAF< 5%) and none were statistically
significant after FDR correction.
Validation and meta-analysis
A stage 2 analysis of rs4969239 (OR = 1.07, 95% CI =
0.83–1.39; p = 5.78 × 10–1 and rs9913477 (OR = 0.86,
95% CI = 0.62–1.18; p = 3.56 × 10–1) failed to validate
their association with BC at a nominal p value. However,
when meta-analyzed with the original dataset, the
association of rs4969239 (OR = 1.29, 95% CI = 1.16–1.44);
p = 4.18 × 10–6) and rs9913477 (OR = 1.33, 95% CI = 1.17–
1.51; p = 1.60 × 10–5) with BC remained directionally
consistent (Table 4).
Power calculations for the detection of a SNP associ-
ated with BC at ORs of 1.44 and 1.30 at a significance of
p ≤ 0.05 indicated that validation among the study set
undergoing the second phase of genotyping was 97%
and 77%, respectively.
Discussion
In a combined analysis of four large studies of BC in AA
women, we identified and annotated a novel genomic re-
gion on chromosome 17q25.3 significantly associated with
BC and extended its functional interpretation with a
comprehensive evaluation of miRNA gene sequence.
Specifically, we have localized the BC association signal to
an 8.6-kb region on chromosome 17 marked by four
tightly linked, significantly associated SNPs, with
rs9913477 demonstrating the strongest association. Using
a second phase of genotyping we were unable to validate
the association of either rs4969239 or rs9913477 with BC;
however, in a meta-analysis these SNPs remained direc-
tionally consistent (OR = 1.29 and 1.33, respectively).
Power calculations indicate that the validation analysis was
well powered (97%) at an OR of 1.44 (our original finding
and likely an overestimate of effect size) and slightly under-
powered (77%) at an OR of 1.3, which represents an effect
estimate 10% less that the original OR. No statistically signifi-
cant miRNA SNP associations were identified in the
Table 1 Characteristics of the study population (Continued)
Controls (n = 4687) Cases (n = 3663)
Frequency Mean (SD) or % Frequency Mean (SD) or %
No NA 1613 44.03
Unknown NA 1645 44.91
BWHS, Black Women’s Health Study; CBCS, Carolina Breast Cancer Study; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MEC, Multiethnic
Cohort; NA, not applicable; PR, progesterone receptor; SD, standard deviation; WCHS, Women’s Circle of Health Study
Fig. 1 Manhattan plot of miRNA SNP and breast cancer risk in the four-site AMBER Consortium (n = 8350, with 3663 cases and 4687 controls). The
green line represents a significant p value threshold of 1 × 10−6 at a false discovery rate (FDR) of 5%
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subanalyses of hormone receptor-negative tumors. Addition-
ally, a case-only analysis that encompassed comparisons of
hormone receptor status, luminal versus basal-like
subtypes, and HER2 enrichment status did not iden-
tify any statistically significant associations with BC
after FDR correction. The most strongly associated
miRNA-associated SNPs for each subtype analysis identi-
fied regions on chromosomes 1p32.3, 5q32, and 3p25.1,
respectively. None of these regions or SNPs have been
previously implicated in BC GWAS according to the
GWAS Catalog (release dated 12 June 2016) [43].
Given their genomic location within the intron of
BAIAP2 and pri-MIR3065 sequence, these four SNPs have
the potential to impact BAIAP2 expression, BAIAP2 gene
intron 1 binding proteins, and/or MIR3065 biogenesis. Ma-
ture MIR3065 resides in a gene adjacent to BAIAP2 known
as apoptosis-associated tyrosine kinase (AATK) where it is
located in the seventh intron and is transcribed in the op-
posite direction from its host gene. In this gene (AATK)
and miRNA-rich region, mature MIR3065 and mature
MIR338 share the same genomic location but are tran-
scribed from opposite DNA strands (Fig. 2) [44]. This crit-
ical miRNA sequence region is highly conserved across
species [44].
To better understand the implications of inherited sus-
ceptibility to BC that may involve BAIAP2, we examined
expression of this gene in human tissues using data from
the Genotype-Tissue Expression (GTEx) project portal
version 6 [45]. Human brain-specific angiogenesis in-
hibitor 1-associated protein 2 (BAIAP2) demonstrates a
range of expression across various human tissues includ-
ing brain and breast [45] (Additional file 2: Figure S1).
Using data from the Human Protein Atlas project that
includes immunochemistry results on 83 different nor-
mal cell types from 44 tissue types, we note that moder-
ate BAIAP2 protein expression is observed in human
breast tissue when compared with other normal tissue
types [46, 47]. Furthermore, when examining RNA
Table 2 Association of the top seven miRNA SNPs with p < 5 × 10−6 and breast cancer risk
SNP Chromosome:positiona Effect/other
allele
EAF OR (95% CI) pb FDR pc INFO (r2)
rs142882938 17:79010031 C/CT 0.06 1.45 (1.24–1.70) 5.9 × 10–7 0.03 0.97
rs4969239d 17:79010544 G/A 0.08 1.35 (1.20–1.52) 1.4 × 10–6 0.06 –
rs28585511 17:79010609 T/A 0.06 1.45 (1.26–1.66) 5.8 × 10–7 0.03 0.98
rs4969351 17:79011141 A/G 0.08 1.35 (1.20–1.52) 3.4 × 10–6 0.11 0.99
rs9913477 17:79015698 G/A 0.06 1.44 (1.26–1.65) 3.2 × 10–7 0.03 0.99
rs7502931 17:79018677 G/A 0.06 1.44 (1.26–1.65) 3.4 × 10–7 0.03 0.99
rs4969366d 17:79026572 G/A 0.05 1.45 (1.24–1.70) 1.5 × 10–6 0.06 –
The seven single nucleotide polymorphisms (SNPs) are intronic to BAIAP2 and located in the primary transcript of miR-3065
Significant FDR results are shown in bold
CI, confidence interval; EAF, effect allele frequency; FDR, false discovery rate; INFO, imputation quality score; OR, odds ratio
aHuman Genome GRCh37/hg19 assembly, NT_010783.15
bAdditive genetic models were adjusted for age group (by ~ 10-year intervals), study site, geographic region of residence, DNA source, and ancestry (PCs 5, 6, and
8 associated with cancer trait, p < 0.1). Sample size: 3663 cases and 4687 controls
cAdjustment for multiple comparisons using the FDR
dGenotyped SNPs, with the other SNPs having been imputed to 1000 Genome Project data
Table 3 Top SNP hits for breast cancer subtype analyses
Breast Cancer Subtype Hormone Receptor +/− Luminal / Basal-like HER2 +/−
Sample size 2081/997 1613/405 1356/344
SNP ID rs80339298 rs147821319 rs116367195
Chromosome:Position* 1:52244019 5:149217038 3:15693446
Effect/Other A/G A/G G/A
Reference Sequence NT_032977.10 NM_001172698 NM_001195099
OR (95%CI) 2.11 (1.54, 2.89) 2.20 (1.52, 3.19) 2.70 (1.72, 4.24)
EAF 0.02 0.04 0.97
p-value** 2.90 × 10−6 2.34 × 10−5 1.59 × 10−5
FDR p-value*** 0.16 0.37 0.84
Abbreviations: OR: odds ratio; 95% CI of the OR; EAF: effect allele frequency; FDR: false discovery rate
* Chromosome: position from GRCh37/hg19 Assembly
** Additive genetic model was adjusted for age group (by ~ 10 year intervals), study site, geographic region of residence, DNA source, and ancestry (PCs 5, 6 and
8 - associated with cancer trait, p-value< 0.1)
***Adjustment for multiple comparisons using the False Discovery Rate (FDR) within each subtype analysis
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sequencing gene expression of BAIAP2 in 47 invasive
breast carcinoma cell lines from the Cancer Cell Line
Encyclopedia [48], we note differential expression with
the highest levels (10-fold or more) of BAIAP2 occurring
in four cell lines: EFM-192A, HCC1937, HCC202, and ZR-
75-30. Of these four cell lines, two are derived from meta-
static sites, with one of these from an African-American
woman, the other Caucasian. Of the remaining two cell lines
(HCC1937, HCC202), both are from Caucasian women,
from primary ductal carcinoma, are ER and PR negative, p53
mutation negative, and positive for EFP2 and CK19
expression; however, they differed in BRCA1 mutation and
HER2 status.
The 17q25.3 region containing the top four BC-
associated SNPs is extensively marked in the human
mammary epithelial cell (HMEC) line by regulatory
chromatin states from DNase and histones H3K27ac
and H3K4me1, reflecting a number of active promoter
and enhancer sequences in the region [44, 49–54].
Furthermore, a number of regulatory sequence motifs (e.g.
, sequence-specific binding sites for transcription factors)
located within intron 1 of BAIAP2 are altered by these
SNPs. Specifically rs9913477 alters regulatory motifs for
CDP1 and SOX3 binding while rs7502931 alters a regula-
tory motif for ZNF143 [55]. No expression quantitative
trait loci (eQTL) were identified in GTEx for any of the
four top SNPs [45].
Several epidemiological studies, including both admixture
mapping and association analysis of the insulin-related
pathway, have examined the 17q region for association with
BC in AMBER. A recently published genome-wide case-
only admixture scan using 2624 AIMs in the AMBER
consortium identified a novel region of excess African an-
cestry associated with BC risk at 17q25.1 (confirmed in a
case-control admixture analysis in the same consortium)
[56]. In this admixture scan, AIM rs496948172 provided
the largest Z score and marked a wide 17q25.1 region of
approximately 4.6 Mb where Z scores remained above 3.7
Table 4 Stages 1 and 2 and meta-analysis of rs9913477 and rs4969239 located in the primary transcript of miR-3065
SNP Chromosome:Positiona Effect/other allele Stageb Sample
size
EAF OR (95% CI) p
rs4969239 17:79010544 G/A Stage 1 8350 0.08 1.35 (1.2–1.52) 1.40 × 10–6
Stage 2 3814 0.08 1.07 (0.83–1.39) 5.78 × 10–1
Meta-analysis 12,164 0.08 1.29 (1.16–1.44) 4.18 × 10–6
rs9913477 17:79015698 G/A Stage 1 8350 0.06 1.44 (1.30–1.58) 3.15 × 10–7
Stage 2 3815 0.06 0.86 (0.62–1.18) 3.56 × 10–1
Meta-analysis 12,165 0.06 1.33 (1.17–1.51) 1.60 × 10–5
CI, confidence interval; EAF, effect allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism
aHuman Genome GRCh37/hg19 assembly, NT_010783.15
bStage 1 model: Additive genetic models were adjusted for age group (by ~ 10-year intervals), WCHS study site, geographic region of residence, DNA source, and
ancestry (PCs 5, 6 and 8 associated with cancer trait, p < 0.1); Stage 2 model: Additive genetic models were adjusted for age group (by ~ 10-year intervals), DNA
source, and ancestry (PCs 1); Meta-analysis was performed in METAL [67]; heterogeneity I2 = 88.1 for rs9913477 and 58.1 for rs4969239
Fig. 2 Chromosome 17 position GRCh37/hg19: 79,008,947–79,105,748, encompassing breast cancer-associated SNPs, defined promoter, primary,
precursor, mature and 3’-UTR, miR-3065 gene regions and other overlapping coding genes. Note: BAIAP2 and AATK are transcribed in opposite directions.
Additionally, AATK contains three more miRNAs in close proximity to miR-3065: miR-657, miR-338 and miR-1250
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indicating excess African ancestry associated with BC. Ele-
vated Z scores of 2.4 for this case analysis extend into the
17q25.3 region, where the top hit for the current associ-
ation analysis (rs9913477) is approximately 1 Mb from the
top admixture hit (rs4969481), although LD between these
variants is limited (D’ = 0.19, r2 = 0.0009) based on AFR
1000 Genomes reference panel [57]. Thus, the region of
excess African ancestry associated with BC marked by an
AIM at 17q25.1 could include the more distal 17q25.3
region as well, providing evidence that variation in this
genomic region associated with BC may contribute to
disparity in risk. A second AMBER gene-based analysis of
184 genes in the insulin/insulin-like growth factor, leptin,
and growth hormone pathways identified BAIP2 and
CALM2, and AIAP2 and CSNK2A1 as the most significant
gene associations (gene-based p ≤ 0.01) with both overall
and ER positive BC, respectively [58]. Thus, both admixture
and insulin pathway-specific association analyses in
AMBER provide suggestive evidence of an association with
overall and ER-positive BC in the 17q21–25 region. How-
ever, due to the relatively less dense SNP set used to evalu-
ate this genomic region in the admixture scan and the less
granular nature of the gene-based insulin pathway analysis,
neither identified the specific set of four miRNA-associated
SNPs localizing a statistically significant association with
BC reported here. Additionally, each study strategy for mul-
tiple test correction varied in accordance with its statistical
methods, with the admixture analysis using a more conser-
vative Bonferroni correction, the gene-based method utiliz-
ing a gene-level correction factor, and our current study
using a false discovery rate.
A recently published epidemiological study examining
miRNA genes and BC among women of African ances-
try found fourteen miRNA SNPs associated with overall
BC risk at the significance level of 0.05 [29]. Included
among these SNPs was rs73410309 within the precursor
sequence of MIR4739 located on chromosome 17q25.3
(OR = 1.1; p = 0.039), which is approximately 1.5 Mb
from our top hit in MIR3065 (rs9913477) and not in
high LD with this SNP (D’ = 0.007 and R2 = 0.0) based
on AFR 1000 Genomes reference panel [57]. This study
was restricted to SNPs within miRNA precursor and
mature sequences and thus would not have included the
SNP in the primary miRNA sequence identified in our
study, but highlights the potential role for miRNA SNPs
in BC risk among women of African ancestry in this
genomic region.
While no GWAS hits have been reported in the
17q25.3 region, this region has been implicated in
several studies of BC tissues where recurrent gain of this
genomic region is associated with subtype and recur-
rence [59, 60]. Gene expression studies of 17q25.3 have
identified significant overexpression of 17q25.3 genes in
BRCA1 mutated triple-negative breast cancer (TNBC)
as compared with BRCA1 nonmutated TNBC [59],
highlighting the important role that overexpressed sets
of genes in this region may play in BC. Given the major
role that miRNAs play in global gene regulation it is
possible that, even in the absence of a copy number
gain, abnormal expression of miRNA genes intended to
suppress expression across multiple oncogenes could
lead to similar upregulation of sets of genes in this re-
gion with similar BC effect. Studies of higher-order
chromatin organization have identified regional epigen-
etic regulation (RER) in breast tumors and BC cell lines
that are independent of copy number [61], where 26 re-
gions of coordinate expression were identified between
breast tumors and BC cell lines with nine RER showing
upregulated gene expression relative to normal breast
tissue. Included among these upregulated regions was a
0.9-Mb 17q25.1 region with correlated expression of
KCTD2, GGA3, MRPS7, and GRB2, and a 0.58-Mb
17q25.3 region (approximately 900 kb from the four as-
sociated SNPs reported here) with correlated expres-
sion of STRA13, RFNG, CSNK1D, and SECTM1.
Perhaps the most compelling support implicating
MIR3065 and BC comes from a recent study by Perrson et
al. in which NGS expression analysis in paired normal and
breast tumor tissue demonstrates a strikingly disparate ex-
pression pattern for MIR3065 [18]. Among the 361 newly
NGS identified miRNA precursors, tumor identity was de-
fined by differences in expression level of a large and com-
mon set of miRNAs rather than tissue specific expression
[18]. While tissue MIR3065 expression was highest in
breast tumors in a panel of nine human tissues, both lung
and placenta demonstrated the next highest expression
levels. Similar to previous studies, through BAC array com-
parative genomic hybridization (CGH), MIR3065 was also
identified as a gene encoded in a region with high-level
genomic amplification in luminal B, ERBB2/HER2-positive,
ER positive, and ER negative subtypes. Among TargetScan’s
(release 6.2, June 2012) MIR3065 gene top 15 predicted
gene targets are the top hit AT-rich interaction domain 4B,
ARID4B (alias BRCAA1, breast cancer antigen epitope-1)
and RAB22A, a member of the RAS oncogene family of
small GTPases involved in signal transduction [62–65].
Immunohistochemically, ARID4B/BRCAA1 was expressed
in 65% of BC specimens but not in noncancerous tissues.
and expression was closely associated with ER- and PR-
positive status [66]. BC patients also had significantly higher
titers of this epitope than healthy donors (p < 0.001). Given
that two of the top predicted targets are likely oncogenes, it
is possible that the role of MIR3065 is to suppress expres-
sion of these oncogenes. It is also possible that the pri-
MIR3065 SNP associated with BC (or a SNP in LD) impairs
MIR3065 processing, leading to lower levels of mature
MIR3065 and reduced inhibition of these oncogenes. Of
course, specific gene targets of this new miRNA are not yet
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fully known and new information may emerge as target
prediction algorithms improve and functional data become
available. For example, in addition to supporting the poten-
tial role of MIR3065 in BC, Perrson et al. also uncovered a
new miRNA in a very well-studied region within the intron
of ERBB2/HER2, a major predictive marker in BC [18].
This discovery highlights the importance of evaluating gen-
omic regulation beyond the protein coding gene level to
examine the major role that noncoding genes, such as miR-
NAs, may play in cancer development and heterogeneity.
These insights will prove invaluable in our understanding
of disease development, identifying at-risk populations and
providing targets for cancer treatment.
Although this study was limited in scope to miRNAs
with SNPs represented or imputed from the Illumina
Human Exome BeadChip v1.1 and AMBER custom con-
tent (and thus only surveys one-third of all SNPS in the
miRBase), as well as by miRNAs with predicted primary
sequence from six cell lines, this study is one of the largest
evaluations of miRNAs for association with BC. Moreover,
it is the largest investigation among African-American
women with BC annotated for subtype. Furthermore, pre-
dicted boundaries of primary transcripts at both 5′ and 3′
ends were extended from the start of the H3K4me3 peak
at the 5′ end (which is often upstream from the actual
transcription start site (TSS)) and through the end of the
H3K79me2 or H3K36me3 signal (which may or may not
be downstream of the transcription termination site).
Thus, SNPs defined as retained within the primary tran-
script may reside just upstream in the miRNA promoter
region or may reside just downstream beyond the 3′ end
of the primary transcript, thus potentially altering our in-
terpretation of function. Specifically, we predicted that the
BC-associated SNPs identified may affect miRNA process-
ing; however, if in fact they reside in the promoter regions,
they may influence miRNA expression through other
mechanisms. More experimental validation of discrete
TSS and end sites is needed for the majority of known
miRNAs. Additionally, while this is one of the largest pop-
ulations of African-Americans with BC examined for
miRNA gene association, the subtype analyses remain
underpowered for the genetic effect sizes anticipated.
Despite these limitations, this study provides valuable
new information about the relationship between numerous
miRNA genes and BC in an understudied population,
African-American women. It emphasizes the complexity of
SNP association analyses and interpretation of function in
gene-dense regions, and also the complex interplay of evi-
dence from studies of coding genes, copy number variation,
epigenetic regulation, and admixture mapping in an
important chromosomal region associated with BC.
Functional assessment of the BC-associated SNPs in
BAIAP2 and MIR3065 are needed to identify the potential
molecular mechanism behind their association with BC
risk, in particular the risk of ER positive BC, the most com-
mon subtype. Larger studies of African-American women
are needed to address subtype-specific biology and genetics,
including those related to miRNAs.
Conclusions
This study reports a novel BC signal within an 8.6-kb locus
on chromosome 17q25.3, where germline genetic variation is
associated with overall and ER positive BC risk among
African-American women. This complex and gene-dense re-
gion contains BAIAP2, a protein-coding gene, and MIR3065,
an important nonprotein coding regulatory gene, which may
play key roles in BC development and heterogeneity among
AA women. An understanding of the potentially functional
implications of variation in these genes is necessary and may
uncover important genetic risk factors and mechanisms for
BC in general and, more specifically, for ER positive BC, the
most common subtype. Understanding risk factors and
mechanisms for BC may lead to improved screening, risk
stratification, and novel treatments.
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